ClinicalTrials.gg
Drug

Aumolertinib clinical trials

Also written Almonertinib and HS-10296.

studies test it
50
open now
20
in phase 3
15
first study started
2017

How each study uses aumolertinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the aumolertinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
12 Feb 2026 · Aumseqa · EMEA/H/C/006069 (EMA; now revoked)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Aumolertinib
9
Investigational Product
3

Development codes

HS-10296
16
EQ143
1

Other names

Almonertinib
28
Almonertinib 110 MG
1

In one entry with another drug

Given together, or one or the other

Almonertinib plus carboplatin and pemetrexed
2

Studies by the year they started

50 studies that test it; most in 2021 (15)

Studies that test aumolertinib, by start year
YearStudies
20171
20192
20208
202115
20229
20235
20245
20253
20262

By phase

A phase 1/2 study counts in both.

Phase 1
7
Phase 2
29
Phase 3
15
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 15 · Other 35

Jiangsu Hansoh Pharmaceutical Co., Ltd. (8) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (3) · Sun Yat-sen University (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Shanghai Pulmonary Hospital, Shanghai, China (2) · EQRx International, Inc. (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Qianfoshan Hospital (2)

Often tested with

Tested in the same studies.

Ruzaltatug rezetecan (2) · Pemetrexed (1) · Cisplatin (1) · Adebrelimab (1) · C-Met Inhibitor HS-10241 (1) · Anlotinib (1) · SHR-1701 (1) · Microwave Ablation (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5, 1 in phase 3

Studies that test aumolertinib, phase 3 first.

Studies

Open first, then newest update. How each study uses aumolertinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 50

See all 50 studies that test aumolertinib →

Given beside what is tested · 6 — aumolertinib is usual care or a partner of the new treatment

Codes

What other systems call aumolertinib · ClinicalTrials.gg INT001649

  • MeSH (NLM) C000718108aumolertinibOne source NLM
  • UNII (FDA) T4RS462G19AUMOLERTINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q105317437aumolertinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C133691AumolertinibOne source FDA
  • DrugBank DB16640One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.